February 14, 2017, New York, NY – The Food and Drug Administration (FDA) has named Suzanne Robotti, founder and president of MedShadow Foundation, to its Drug Safety and Risk Management Advisory Committee as the Consumer Representative. Next month, she will attend her first hearing where a prescription opioid drug will be discussed.
The committee advises the FDA commissioner on risk management, risk communication, and quantitative evaluation of adverse event reports for drugs for which the FDA has regulatory responsibility. The committee also advises the commissioner regarding the scientific and medical evaluation of all information gathered by the Department of Health and Human Services (HHS) and the Department of Justice with regard to safety, efficacy, and abuse potential of drugs or other substances. It also recommends actions to be taken by HHS with regard to the marketing, investigation, and control of such drugs or other substances.
Robotti applied for the role in response to the FDA’s outreach for qualified experts with minimal conflicts of interest. Candidates for the volunteer positions must be able to analyze detailed scientific data and understand its public health significance. Robotti was chosen as the sole consumer representative of the committee.
About MedShadow Foundation
MedShadow Foundation is an online nonprofit 501©(3) that educates consumers about the side effects, long-term impacts, risks and benefits of medications, both over-the-counter and prescription. Founded in 2012 by Suzanne Robotti, a health advocate, MedShadow uses its website and social media platforms to gather and report news as well as provide resources that empower consumers and create opportunities for deeper discussion with their health practitioner. In 2016, MedShadow was given the prestigious designation Great Nonprofit. For more information, visit www.medshadow.org.